RxDoctor Payments Data

Caroline Hage Rouzeau, MD

Family Medicine · Fort Myers, FLNPI 1467860544

Payments from drug & device makers

$545in general payments, 2019–2025

Across 32 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$175
  • AstraZeneca$132
  • Pfizer$55
  • GSK$43
  • Merck$41
  • Lilly USA, LLC$36
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,934
Medicare patients
54
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$101,275
OzempicSemaglutide62$58,881
LinzessLinaclotide73$53,572
Janumet XrSitagliptin Phos/Metformin Hcl42$48,795
XareltoRivaroxaban35$41,751
TrulicityDulaglutide38$41,707
EliquisApixaban49$38,942
JanuviaSitagliptin Phosphate23$35,600
MounjaroTirzepatide29$31,051
FarxigaDapagliflozin Propanediol23$28,031
CreonLipase/Protease/Amylase30$20,118
GlyxambiEmpagliflozin/Linagliptin12$16,340
SymbicortBudesonide/Formoterol Fumarate38$9,729
Synjardy XrEmpagliflozin/Metformin Hcl13$7,849
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr$175$125,46490 claims
MerckJanumet Xr, Januvia$41$84,39465 claims
Lilly USA, LLCTrulicity, Mounjaro$36$72,75867 claims
Novo NordiskOzempic$22$58,88162 claims
PfizerEliquis$55$38,94249 claims
AstraZenecaFarxiga, Symbicort$132$37,76161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →